Notification That Annual Report Will Be Submitted Late (nt 10-k)
31 Marzo 2014 - 3:00PM
Edgar (US Regulatory)
|
|
|
|
|
OMB
APPROVAL
|
OMB Number:
|
|
3235-0058
|
Expires:
|
|
April 30, 2009
|
Estimated average burden
|
hours per response
|
|
2.50
|
SEC FILE NUMBER
|
CUSIP NUMBER
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
|
|
|
(Check One)
|
|
x
Form 10-K
¨
Form 20-F
¨
Form 11-K
¨
Form 10-Q
¨
Form
10-D
¨
Form N-SAR
¨
Form N-CSR
|
|
|
|
|
For Period Ended: 12/31/13
|
|
|
|
|
¨
Transition Report on Form 10-K
|
|
|
¨
Transition Report on Form 20-F
|
|
|
¨
Transition Report on Form 11-K
|
|
|
¨
Transition Report on Form 10-Q
|
|
|
¨
Transition Report on Form N-SAR
|
|
|
|
|
For the Transition Period Ended:
|
|
Read Instruction (on back page)
Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any
information contained herein.
|
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART I REGISTRANT
INFORMATION
Alseres Pharmaceuticals, Inc.
Full Name of Registrant
Former Name if Applicable
275 Grove Street, Suite 2-400
Address of Principal Executive Office (
Street and Number
)
Auburndale, MA 02466
City, State and Zip Code
PART II RULES 12b-25(b)
AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
|
|
|
|
|
¨
|
|
(a)
|
|
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense.
|
x
|
|
(b)
|
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be
filled on or before the fifth calendar day following the prescribed due date: and
|
¨
|
|
(c)
|
|
The accountants statement or other exhibit is required by Rule 12b-25(c) has been attached if applicable.
|
PART III NARRATIVE
State below in
reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
The registrant is a very small company with extremely limited resources. Due to the severe resource constraints on the company, we had only one person
responsible for preparing all the requisite backup materials for the Form 10-K filing and for interfacing with the registrants registered independent public accounting firm, We will file the form 10-K within the prescribed 15 business days if
not sooner and we do not expect this type of delay to recur.
(Attach Extra Sheets if Needed)
SEC 1344 (05-06)
PART IV OTHER
INFORMATION
(1)
|
Name and telephone number of person to contact in regard to this notification
|
|
|
|
|
|
|
|
|
|
Kenneth L. Rice Jr.
|
|
|
|
781
|
|
|
|
929-2639
|
(Name)
|
|
|
|
(Area Code)
|
|
|
|
(Telephone Number)
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the investment Company Act of 1940 during the preceding 12 months or for such shorter period
that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). Yes
¨
No
x
|
Form 10-Q for the period ended March 31, 2013.
(3)
|
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion
thereof? Yes
¨
No
x
|
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Date:
|
|
March 31, 2014
|
|
|
|
By:
|
|
|
|
/s/ Kenneth L. Rice Jr. EVP & CFO
|
|
|
|
|
|
|
Name and Title
|
Alseres Pharmaceuticals (CE) (USOTC:ALSE)
Gráfica de Acción Histórica
De Ene 2025 a Feb 2025
Alseres Pharmaceuticals (CE) (USOTC:ALSE)
Gráfica de Acción Histórica
De Feb 2024 a Feb 2025